Acute-onset severe gastrointestinal tract hemorrhage in a postoperative patient taking rivaroxaban after total hip arthroplasty: A case report

Journal of Medical Case Reports

Volumn 6, Issue , 2012, Pages

  Boland, Michael ^a   Murphy, Maria ^a   Murphy, Marese ^a   McDermott, Enda ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

GELATIN SUCCINATE; HEMOGLOBIN; PROTON PUMP INHIBITOR; RIVAROXABAN;

ABDOMINAL TENDERNESS; ADULT; ANTICOAGULANT THERAPY; ARTICLE; CASE REPORT; CAUCASIAN; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FOLLOW UP; GASTRITIS; GASTROINTESTINAL ENDOSCOPY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTENSION; INTRAVENOUS ADMINISTRATION; MALE; PALLOR; POSTOPERATIVE CARE; PRIORITY JOURNAL; RECTUM HEMORRHAGE; SURGICAL PATIENT; TOTAL HIP PROSTHESIS; TREATMENT RESPONSE;

EID: 84860821887     PISSN: None     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-6-129     Document Type: Article

References (7)

1. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W, RECORD1 Study Group, N Engl J Med 2008 358 26 2765 2775 10.1056/NEJMoa0800374 18579811 (Pubitemid 351930851)
2. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double blind randomised controlled trial. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S, RECORD2 Investigators, Lancet 2008 372 9632 31 39 10.1016/S0140-6736(08)60880-6 18582928
3. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG, RECORD3 Investigators, N Engl J Med 2008 358 26 2776 2786 10.1056/NEJMoa076016 18579812 (Pubitemid 351930852)
4. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD, RECORD4 Investigators, Lancet 2009 373 9676 1673 1680 10.1016/S0140-6736(09)60734-0 19411100
5. Oral rivaroxaban for symptomatic venous thromboembolism. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S, EINSTEIN Investigators, N Engl J Med 2010 363 26 2499 2510 21128814
6. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM, ATLAS ACS-TIMI 46 study group, Lancet 2009 4 9683 29 38
7. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M, Circulation 2011 124 14 1573 1579 10.1161/CIRCULATIONAHA.111.029017 21900088